EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Eisenmenger syndrome: current perspectives

Heba Nashat, Aleksander Kempny, Colm McCabe, Laura C Price, Carl Harries, Rafael Alonso-Gonzalez, Michael A Gatzoulis, Stephen J Wort, Konstantinos Dimopoulos

Research Reports in Clinical Cardiology · 2017

DOI: 10.2147/rrcc.s117838 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research Reports in Clinical Cardiology, 2017. Verfasst von Heba Nashat und 8 weiteren Autor:innen. Die Arbeit wurde bisher 9-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eisenmenger syndrome (ES) is the most severe form of pulmonary arterial hypertension (PAH) related to congenital heart disease (CHD). It results from a cardiac defect allowing significant systemic-to-pulmonary (left-to-right) shunting, which triggers the development of pulmonary vascular disease (PVD) if the defect is not repaired in a timely fashion. Once severe PVD has developed, the defect cannot be repaired. With advances in pediatric cardiology and surgery, the prevalence of ES is steadily falling in developed countries; nonetheless, there will always be patients who are unsuitable for repair at the time of diagnosis, or emigrating from countries with less advanced healthcare, who will develop ES. ES is a multisystem disorder causing chronic hypoxemia and reduced cardiac output resulting in significant morbidity and mortality. While lung (plus defect repair) or combined heart and lung transplantation is thought be the definitive treatment for ES, transplant organs are a limited resource and long-term results are still suboptimal. PAH pharmacotherapy was, until quite recently, largely directed at symptomatic relief and had no impact on morbidity and mortality. Targeted PAH therapies have recently been proven to be beneficial in various forms of PAH in terms of functional status, progression of disease, and prognosis. Data on the effect of PAH therapies in the ES cohort remain limited, but available studies demonstrate evidence of improvement in symptoms, exercise capacity, and some evidence of survival benefit. ES patients should be followed in specialized centers, by means of an interdisciplinary approach by clinicians experienced in PAH and CHD. However, local physicians working in cardiology, respiratory medicine, primary care, and emergency services are likely to encounter ES patients and need to be aware of the main issues and pitfalls in their care. The authors present an overview of the management of ES, focusing on the most common issues and complications. Keywords: Eisenmenger syndrome, pulmonary arterial hypertension, congenital heart disease, cyanosis, pulmonary arterial hypertension therapies, hyperviscosity, thrombosis, bleeding, pregnancy, Down syndrome

Zitieren

APA

Nashat, H., Kempny, A., McCabe, C., Price, L. C., Harries, C., Alonso-Gonzalez, R., Gatzoulis, M. A., Wort, S. J., & Dimopoulos, K. (2017). Eisenmenger syndrome: current perspectives. Research Reports in Clinical Cardiology. https://doi.org/10.2147/rrcc.s117838

Vancouver

Nashat H, Kempny A, McCabe C, Price LC, Harries C, Alonso-Gonzalez R, et al. Eisenmenger syndrome: current perspectives. Research Reports in Clinical Cardiology. 2017. doi:10.2147/rrcc.s117838

BibTeX
@article{Nashat2017,
  author = {Nashat, Heba and Kempny, Aleksander and McCabe, Colm and Price, Laura C and Harries, Carl and Alonso-Gonzalez, Rafael and Gatzoulis, Michael A and Wort, Stephen J and Dimopoulos, Konstantinos},
  title = {Eisenmenger syndrome: current perspectives},
  journal = {Research Reports in Clinical Cardiology},
  year = {2017},
  doi = {10.2147/rrcc.s117838}
}
Kostenlos starten →